
Canagliflozina es el único iSGLT2 aprobado en Europa para el tratamiento de la enfermedad renal diabética en pacientes con DM2
febrero 24, 2021 2:14 pmLa Comisión Europea ha aprobado la extensión de indicación
La Comisión Europea ha aprobado la extensión de indicación
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.